TAS-102

You have access
Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer
TETSUO ISHIZAKI, JUNICHI MAZAKI, MASANOBU ENOMOTO, MASATOSHI SHIGOKA, KENTA KASAHARA, TAKAAKI MATSUDO, HIDEAKI KAWAKITA, YUICHI NAGAKAWA, KENJI KATSUMATA and AKIHIKO TSUCHIDA

Anticancer Research April 2021, 41 (4) 2157-2163; DOI: https://doi.org/10.21873/anticanres.14988
You have access
Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment
YUSUKE NIISATO, TOSHIKAZU MORIWAKI, SHOTA FUKUOKA, TOSHIKI MASUISHI, ATSUO TAKASHIMA, YOSUKE KUMEKAWA, TAKESHI KAJIWARA, KENTARO YAMAZAKI, TAITO ESAKI, AKITAKA MAKIYAMA, TADAMICHI DENDA, YUKIMASA HATACHI, TAKESHI SUTO, NAOTOSHI SUGIMOTO and YASUHIRO SHIMADA

Anticancer Research April 2021, 41 (4) 2203-2207; DOI: https://doi.org/10.21873/anticanres.14996
You have access
Combining Bevacizumab With Trifluridine/Thymidine Phosphorylase Inhibitor Improves the Survival Outcomes Regardless of the Usage History of Bevacizumab in Front-line Treatment of Patients With Metastatic Colorectal Cancer
MASATSUNE SHIBUTANI, HISASHI NAGAHARA, TATSUNARI FUKUOKA, YASUHITO ISEKI, EN WANG, YUKI OKAZAKI, SHINICHIRO KASHIWAGI, KIYOSHI MAEDA, KOSEI HIRAKAWA and MASAICHI OHIRA

Anticancer Research July 2020, 40 (7) 4157-4163; DOI: https://doi.org/10.21873/anticanres.14415
You have access
Pretreatment Neutrophil–to–Lymphocyte Ratio Predicts Survival After TAS-102 Treatment of Patients With Metastatic Colorectal Cancer
AKIHISA MATSUDA, TAKESHI YAMADA, SATOSHI MATSUMOTO, NOBUYUKI SAKURAZAWA, YOUICHI KAWANO, ERIKO SHINOZUKA, KUMIKO SEKIGUCHI, HIDEYUKI SUZUKI and HIROSHI YOSHIDA

Anticancer Research August 2019, 39 (8) 4343-4350; DOI: https://doi.org/10.21873/anticanres.13602
You have access
Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer
MICHIO KIMURA, EISEKI USAMI, HITOMI TERAMACHI and TOMOAKI YOSHIMURA

Anticancer Research February 2019, 39 (2) 1029-1034; DOI: https://doi.org/10.21873/anticanres.13209
You have access
Biweekly Administration of TAS-102 for Neutropenia Prevention in Patients with Colorectal Cancer
YOICHIRO YOSHIDA, RYOHEI SAKAMOTO, RYUJI KAJITANI, TARO MUNECHIKA, YOSHIKO MATSUMOTO, AKIRA KOMONO, NAOYA AISU, KOJIMA DAIBO, FUMIHIKO KIYOMI and SUGURU HASEGAWA

Anticancer Research July 2018, 38 (7) 4367-4373; DOI: https://doi.org/10.21873/anticanres.12738
You have access
Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
HIDEJIRO KAWAHARA, TAKASHI MOURI, KOTA ISHIDA, NORI MATSUMOTO, TADASHI AKIBA and KATSUHIKO YANAGA

Anticancer Research April 2018, 38 (4) 2419-2422;
You have access
Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies
TOSHINORI SUEDA, DAISUKE SAKAI, TOSHIHIRO KUDO, TAKASHI SUGIURA, HIDEKAZU TAKAHASHI, NAOTSUGU HARAGUCHI, JUNICHI NISHIMURA, TAISHI HATA, TARO HAYASHI, TSUNEKAZU MIZUSHIMA, YUICHIRO DOKI, MASAKI MORI and TAROH SATOH

Anticancer Research August 2016, 36 (8) 4299-4306;
You have access
Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer
SHUJI ARITA, TSUYOSHI SHIRAKAWA, YUZO MATSUSHITA, HOZUMI KUMAGAI SHIMOKAWA, GEN HIRANO, AKITAKA MAKIYAMA, YOSHIHIRO SHIBATA, SHINGO TAMURA, TAITO ESAKI, KENJI MITSUGI, HIROSHI ARIYAMA, HITOSHI KUSABA, KOICHI AKASHI and EISHI BABA

Anticancer Research April 2016, 36 (4) 1959-1966;
You have access
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts
MAMORU NUKATSUKA, FUMIO NAKAGAWA and TEIJI TAKECHI

Anticancer Research September 2015, 35 (9) 4605-4615;

Main menu

User menu

Search

TAS-102

Pages